Undecimal Bio

Company Overview

Snapshot

Founded in July 2025, Undecimal Bio operates with 1–10 employees and has completed one funding round. In January 2026, the company secured Pre-Seed funding from investors including Entrée Capital and Harel Insurance & Finance.

Business overview

Undecimal Bio is an early-stage biotechnology company focused on developing AI-enabled technologies to enhance the scalability and reproducibility of RNA delivery for therapeutic research and development. The company's core technology combines RNA-delivery development with AI-assisted biological data generation and modeling. Undecimal Bio serves pharmaceutical and biotechnology R&D teams working on RNA therapeutics, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drug Delivery.

Company Intelligence Q&A

What is Undecimal Bio's primary focus?

Undecimal Bio develops AI-enabled technologies to industrialize RNA delivery, aiming to make it more scalable and reproducible for therapeutic research and development.

When was Undecimal Bio founded?

Undecimal Bio was founded in July 2025.

What was Undecimal Bio's most recent funding event?

In January 2026, Undecimal Bio secured Pre-Seed funding from Entrée Capital and Harel Insurance & Finance.

Which sector does Undecimal Bio primarily operate in?

Undecimal Bio operates primarily in the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Drug Delivery.

What is the current employee count for Undecimal Bio?

Undecimal Bio currently has 1–10 employees.